$BLCM still holding like BB ownership & data forthcoming: ClinicalTrials.gov ID NCT01823978 w/ results expected during 1H15 for P1 trial in pts w/ metastatic castrate-resistant prostate cancer (mCRPC), plans to begin a P1/2 trial in combination w/ other cancer immunotherapies; for BPX-201 and BPX-501
Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.